Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Free Report)’s share price rose 0.7% on Tuesday . The stock traded as high as $1.55 and last traded at $1.53. Approximately 159,886 shares traded hands during trading, a decline of 26% from the average daily volume of 215,921 shares. The stock had previously closed at $1.52.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on MIST. Rodman & Renshaw began coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 22nd. They issued a “buy” rating and a $9.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Milestone Pharmaceuticals in a research note on Thursday, August 22nd.
Get Our Latest Stock Analysis on MIST
Milestone Pharmaceuticals Stock Performance
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. As a group, analysts predict that Milestone Pharmaceuticals Inc. will post -0.71 earnings per share for the current year.
Hedge Funds Weigh In On Milestone Pharmaceuticals
A hedge fund recently raised its stake in Milestone Pharmaceuticals stock. Lion Point Capital LP raised its stake in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) by 1.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,340,207 shares of the company’s stock after acquiring an additional 40,000 shares during the quarter. Milestone Pharmaceuticals makes up 5.6% of Lion Point Capital LP’s portfolio, making the stock its 3rd largest holding. Lion Point Capital LP owned about 4.39% of Milestone Pharmaceuticals worth $3,089,000 as of its most recent filing with the SEC. Institutional investors own 86.18% of the company’s stock.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Read More
- Five stocks we like better than Milestone Pharmaceuticals
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What Are Trending Stocks? Trending Stocks Explained
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Trading Halts Explained
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.